Science Explorer Back to mapMap
Discussion
Company · Didcot · United Kingdom

Karus Therapeutics (United Kingdom)

karustherapeutics.comROR OpenAlex
Research works
41
▼ 17% vs 2018-21
Citations
795
19.5 per fractional work
Top-10% rate
15.4%
all institutions 10.0%
Open access
20%
world 40%
International
29%
world 18%
Karus Therapeutics (United Kingdom)

Not ranked overall: Karus Therapeutics (United Kingdom) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Karus Therapeutics (United Kingdom) work in?

In all years, 47% of research at Karus Therapeutics (United Kingdom) is in Life Sciences, 42% in Health Sciences. Its largest fields are Medicine (41%), Biochemistry, Genetics and Molecular Biology (40%), Immunology and Microbiology (4%). It does 2.4× the world's share of Life Sciences.

Life Sciences: 19 fractional works · 47.3% of its workBiochemistry, Genetics and Molecular Biology: 16 fractional works · 40.0% of its workMolecular Biology: 14 fractional works · 35.5% of its workBiochemistry: 0 fractional works · 0.8% of its workBiotechnology: 0 fractional works · 0.8% of its workCell Biology: 0 fractional works · 0.8% of its workClinical Biochemistry: 0 fractional works · 0.8% of its workGenetics: 0 fractional works · 0.7% of its workBiophysics: 0 fractional works · 0.4% of its workImmunology and Microbiology: 2 fractional works · 3.8% of its workImmunology: 1 fractional works · 3.4% of its workVirology: 0 fractional works · 0.4% of its workAgricultural and Biological Sciences: 1 fractional works · 3.0% of its workEcology, Evolution, Behavior and Systematics: 1 fractional works · 1.4% of its workAgronomy and Crop Science: 0 fractional works · 1.2% of its workInsect Science: 0 fractional works · 0.4% of its workNeuroscience: 0 fractional works · 0.4% of its workNeurology: 0 fractional works · 0.4% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.2% of its workPharmaceutical Science: 0 fractional works · 0.2% of its workHealth Sciences: 17 fractional works · 42.0% of its workMedicine: 17 fractional works · 40.7% of its workOncology: 5 fractional works · 13.5% of its workPulmonary and Respiratory Medicine: 2 fractional works · 4.8% of its workGenetics: 2 fractional works · 3.7% of its workPharmacology: 2 fractional works · 3.7% of its workPathology and Forensic Medicine: 1 fractional works · 2.6% of its workPhysiology: 1 fractional works · 2.0% of its workEpidemiology: 1 fractional works · 1.8% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 1.5% of its workHematology: 1 fractional works · 1.5% of its workNeurology: 0 fractional works · 1.0% of its workSurgery: 0 fractional works · 1.0% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.8% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.8% of its workInfectious Diseases: 0 fractional works · 0.7% of its workTransplantation: 0 fractional works · 0.5% of its workDermatology: 0 fractional works · 0.3% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.3% of its workNursing: 0 fractional works · 0.8% of its workNutrition and Dietetics: 0 fractional works · 0.8% of its workHealth Professions: 0 fractional works · 0.4% of its workGeneral Health Professions: 0 fractional works · 0.4% of its workPhysical Sciences: 3 fractional works · 6.6% of its workChemistry: 1 fractional works · 3.2% of its workOrganic Chemistry: 1 fractional works · 1.9% of its workInorganic Chemistry: 1 fractional works · 1.3% of its workComputer Science: 1 fractional works · 1.9% of its workInformation Systems: 1 fractional works · 1.5% of its workComputer Science Applications: 0 fractional works · 0.4% of its workEnergy: 0 fractional works · 0.4% of its workRenewable Energy, Sustainability and the Environment: 0 fractional works · 0.4% of its workEnvironmental Science: 0 fractional works · 0.4% of its workEcology: 0 fractional works · 0.4% of its workMaterials Science: 0 fractional works · 0.4% of its workBiomaterials: 0 fractional works · 0.4% of its workEngineering: 0 fractional works · 0.1% of its workMathematics: 0 fractional works · 0.1% of its workSocial Sciences: 2 fractional works · 4.1% of its workPsychology: 1 fractional works · 2.3% of its workDevelopmental and Educational Psychology: 1 fractional works · 2.3% of its workSocial Sciences: 1 fractional works · 1.7% of its workPolitical Science and International Relations: 0 fractional works · 1.2% of its workSociology and Political Science: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.2% of its workALL ITS WORKKarusTherapeutics…41fractional works, all years
Life Sciences47%Physical Sciences7%Health Sciences42%Social Sciences4%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 18 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology1640.0%
    2. Immunology and Microbiology23.8%
    3. Agricultural and Biological Sciences13.0%
    4. Neuroscience00.4%
    5. Pharmacology, Toxicology and Pharmaceutics00.2%
    1. Medicine1740.7%
    2. Nursing00.8%
    3. Health Professions00.4%
    1. Chemistry13.2%
    2. Computer Science11.9%
    3. Energy00.4%
    4. Environmental Science00.4%
    5. Materials Science00.4%
    6. Engineering00.1%
    7. Mathematics00.1%
    1. Psychology12.3%
    2. Social Sciences11.7%
    3. Economics, Econometrics and Finance00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Karus Therapeutics (United Kingdom)?

Ranked on the quality score, Stephen Joseph Shuttleworth and Stephen Shuttleworth lead among researchers whose main affiliation is Karus Therapeutics (United Kingdom).

  1. 1 Stephen Joseph Shuttleworth United Kingdom · #1,662,018 worldwide 2.4k citations · 54 works
  2. 2 Stephen Shuttleworth United Kingdom · #3,351,419 worldwide 844 citations · 42 works
All ranked researchers at Karus Therapeutics (United Kingdom)

What are the most cited papers from Karus Therapeutics (United Kingdom)?

The most cited paper from Karus Therapeutics (United Kingdom) is "The Economic Impact of Eradicating Peste des Petits Ruminants: A Benefit-Cost Analysis" (Bryony Anne Jones, Karl M. Rich, Jeffrey C. Mariner et al., 2016), with 148 citations. Next come "Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy" (145) and "Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors" (103).

Most cited papers
#PaperReleasedCitations
1 The Economic Impact of Eradicating Peste des Petits Ruminants: A Benefit-Cost Analysis Bryony Anne Jones, Karl M. Rich, Jeffrey C. Mariner et al. · PLoS ONE Open access 22 Feb 2016 148
2 Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy Dávid Győri, Ee Lyn Lim, Francis M. Grant et al. · JCI Insight Open access 6 Jun 2018 145
3 Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors Stephen Joseph Shuttleworth, F. A. Silva, Alexander Cecil et al. · Current Medicinal Chemistry Open access Jun 2011 103
4 IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo Tania Benatar, Ming Yu Cao, Yoon Lee et al. · Cancer Immunology Immunotherapy Open access 12 Dec 2009 102
5 Participatory Disease Surveillance and Response in Indonesia: Strengthening Veterinary Services and Empowering Communities to Prevent and Control Highly Pathogenic Avian Influenza Muhammad Azhar, Ade S. Lubis, Elly Sawitri Siregar et al. · Avian Diseases Mar 2010 88
All 49 most cited papers, with filters and sorting

Which keywords describe research at Karus Therapeutics (United Kingdom)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer Therapy, Gene Expression, Cancer, Transcriptional Regulation, Epigenetic Regulation, HDAC Inhibitors, Histone Deacetylases and PET Imaging.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer Therapy9▲ 33×8 topics
  2. Cancer4▲ 6.8×9 topics
  3. Gene Expression4▲ 15×3 topics
  4. Epigenetic Regulation3▲ 39×2 topics
  5. HDAC Inhibitors3▲ 426×1 topic
  6. Histone Deacetylases3▲ 426×1 topic
  7. Transcriptional Regulation3▲ 34×3 topics
  8. PET Imaging3▲ 35×3 topics
  9. BET Bromodomains3▲ 355×1 topic
  10. PROTACs3▲ 355×1 topic
  11. Cell Growth3▲ 206×2 topics
  12. Metabolism3▲ 11×3 topics
  13. Signaling3▲ 59×2 topics
  14. Immunosuppression3▲ 57×3 topics
  15. Oxidative Stress2▲ 3.3×8 topics
  16. PI3K/AKT pathway2▲ 283×1 topic
  17. Tumor Microenvironment2▲ 17×2 topics
  18. mTOR2▲ 283×1 topic
  19. Fibroblast Activation Protein2▲ 115×1 topic
  20. N-terminal Acetylation2▲ 115×1 topic
  21. Rituximab2▲ 32×2 topics
  22. Prognostic Factors2▲ 10×4 topics
  23. Metastatic Breast Cancer2▲ 65×2 topics
  24. Tumor Suppression2▲ 36×2 topics
  25. Apoptosis2▲ 9.4×2 topics
  26. Chronic Lymphocytic Leukemia2▲ 76×1 topic
  27. Genomic Aberrations2▲ 76×1 topic
  28. Mutation1▲ 22×2 topics
  29. Cell Cycle1▲ 57×1 topic
  30. Immunotherapy1▲ 5.0×6 topics
  31. p531▲ 75×1 topic
  32. Cell Cycle Control1▲ 120×2 topics
  33. Clinical Trials1▲ 4.8×4 topics
  34. Proteasome Inhibitors1▲ 41×2 topics
  35. Targeted Therapy1▲ 14×4 topics
  36. Breast Cancer1▲ 9.7×1 topic
  37. CDK4/6 Inhibitors1▲ 171×1 topic
  38. Lymphoma1▲ 18×3 topics
  39. Pathogenesis1▲ 4.6×4 topics
  40. Genetic Characterization1▲ 44×2 topics

Which research topics does Karus Therapeutics (United Kingdom) publish most on?

By volume in 2022-now: Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Redox biology and oxidative stress and Fibroblast Growth Factor Research.

Protein Degradation and …0Protein Degradation and Inhibitors: 0 fractional worksPeptidase Inhibition and…0Peptidase Inhibition and Analysis: 0 fractional worksRedox biology and oxidat…0Redox biology and oxidative stress: 0 fractional worksFibroblast Growth Factor…0Fibroblast Growth Factor Research: 0 fractional worksHistone Deacetylase Inhibitors Research: 0 fractional worksLung Cancer Research Studies: 0 fractional worksNeuroblastoma Research a…0Neuroblastoma Research and Treatments: 0 fractional worksNeuroendocrine Tumor Res…0Neuroendocrine Tumor Research Advances: 0 fractional worksLung Cancer Treatments a…0Lung Cancer Treatments and Mutations: 0 fractional worksAdvanced Breast Cancer T…0Advanced Breast Cancer Therapies: 0 fractional works
Molecular BiologyOncologyNeurologyEpidemiology1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Protein Degradation and Inhibitors Molecular Biology 0 works
  2. 2 Peptidase Inhibition and Analysis Oncology 0 works
  3. 3 Redox biology and oxidative stress Molecular Biology 0 works
  4. 4 Fibroblast Growth Factor Research Molecular Biology 0 works
  5. 5 Histone Deacetylase Inhibitors Research Molecular Biology 0 works
  6. 6 Lung Cancer Research Studies Oncology 0 works
  7. 7 Neuroblastoma Research and Treatments Neurology 0 works
  8. 8 Neuroendocrine Tumor Research Advances Epidemiology 0 works
  9. 9 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  10. 10 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available20.3%not open79.7%

World: 40% of research is openly available.

with international co-authors28.7%domestic only71.3%

World: 18% is written across borders.

How has Karus Therapeutics (United Kingdom)'s research output changed?

Output in 2022-2025 was 17% lower than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Karus Therapeutics (United Kingdom) as a percentage of every work published that year, 0.000018% in 2024.

still counting0.00010%0.00020%Karus Therapeutics (United Kingdom)0.000013% in 2025200020102020

Fractional works of Karus Therapeutics (United Kingdom) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Didcot

All research institutions in Didcot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Karus Therapeutics (United Kingdom). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.